Literature DB >> 10602775

Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP).

C Solis1, I Lopez-Echaniz, D Sefarty-Graneda, K H Astrin, R J Desnick.   

Abstract

BACKGROUND: Acute intermittent porphyria (AIP), an autosomal dominant inborn error, results from the half-normal activity of the heme biosynthetic enzyme hydroxymethylbilane synthase (EC 4.3.1.8; HMB-synthase). This disease is characterized by acute, life-threatening neurologic attacks that are precipitated by various drugs, hormones, and other factors. The enzymatic and/or biochemical diagnosis of AIP heterozygotes is problematic; therefore, efforts have focused on the identification of HMB-synthase mutations so that heterozygotes can be identified and educated to avoid the precipitating factors. In Spain, the occurrence of AIP has been reported, but the nature of the HMB-synthase mutations causing AIP in Spanish families has not been investigated. Molecular analysis was therefore undertaken in nine unrelated Spanish AIP patients.
MATERIALS AND METHODS: Genomic DNA was isolated from affected probands and family members of nine unrelated Spanish families with AIP. The HMB-synthase gene was amplified by long-range PCR and the nucleotide sequence of each exon was determined by cycle sequencing.
RESULTS: Three new mutations, a missense, M212V; a single base insertion, g4715insT; and a deletion/insertion, g7902ACT-->G, as well as five previously reported mutations (G111R, R116W, R149X R167W, and R173W) were detected in the Spanish probands. Expression of the novel missense mutation M212V in E. coli revealed that the mutation was causative, having <2% residual activity.
CONCLUSIONS: These studies identified the first mutations in the HMB-synthase gene causing AIP in Spanish patients. Three of the mutations were novel, while five previously reported lesions were found in six Spanish families. These findings enable accurate identification and counseling of presymptomatic carriers in these nine unrelated Spanish AIP families and further demonstrate the genetic heterogeneity of mutations causing AIP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602775      PMCID: PMC2230478     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  25 in total

1.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

2.  Two novel mutations of the porphobilinogen deaminase gene in acute intermittent porphyria.

Authors:  X F Gu; F de Rooij; E de Baar; M Bruyland; W Lissens; Y Nordmann; B Grandchamp
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

3.  Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene.

Authors:  H W Yoo; C A Warner; C H Chen; R J Desnick
Journal:  Genomics       Date:  1993-01       Impact factor: 5.736

4.  Identification of five novel mutations in the porphobilinogen deaminase gene.

Authors:  C S Mgone; W G Lanyon; M R Moore; G V Louie; J M Connor
Journal:  Hum Mol Genet       Date:  1994-05       Impact factor: 6.150

5.  Normal erythrocyte uroporphyrinogen I synthase in a kindred with acute intermittent porphyria.

Authors:  P Mustajoki
Journal:  Ann Intern Med       Date:  1981-08       Impact factor: 25.391

6.  Porphobilinogen deaminase: methods and principles of the enzymatic assay.

Authors:  P M Anderson; R J Desnick
Journal:  Enzyme       Date:  1982

7.  The diagnosis of acute intermittent porphyria. Usefulness and limitations of the erythrocyte uroporphyrinogen I synthase assay.

Authors:  S S Bottomley; H L Bonkowsky; M Kreimer-Birnbaum
Journal:  Am J Clin Pathol       Date:  1981-08       Impact factor: 2.493

8.  Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene.

Authors:  B Grandchamp; H De Verneuil; C Beaumont; S Chretien; O Walter; Y Nordmann
Journal:  Eur J Biochem       Date:  1987-01-02

9.  Restriction sites containing CpG show a higher frequency of polymorphism in human DNA.

Authors:  D Barker; M Schafer; R White
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

10.  Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression.

Authors:  S Chretien; A Dubart; D Beaupain; N Raich; B Grandchamp; J Rosa; M Goossens; P H Romeo
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

View more
  6 in total

1.  Genetic and biochemical characterization of 16 acute intermittent porphyria cases with a high prevalence of the R173W mutation.

Authors:  J To-Figueras; C Badenas; C Carrera; C Muñoz; M Milá; M Lecha; C Herrero
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

2.  Mutation hotspots in the human porphobilinogen deaminase gene: recurrent mutations G111R and R173Q occurring at CpG motifs.

Authors:  X Schneider-Yin; M Hergersberg; M M Schuurmans; A Gregor; E I Minder
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 3.  Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Authors:  Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

4.  Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria.

Authors:  Helene J Bustad; Marta Vorland; Eva Rønneseth; Sverre Sandberg; Aurora Martinez; Karen Toska
Journal:  Biosci Rep       Date:  2013-08-08       Impact factor: 3.840

5.  Many pitfalls in diagnosis of acute intermittent porphyria: a case report.

Authors:  N L R Indika; T Kesavan; H W Dilanthi; K L S P K M Jayasena; N D P D Chandrasiri; I N Jayasinghe; U M T Piumika; D M Vidanapathirana; K D A V Gunarathne; M Dissanayake; E Jasinge; W Kodikara Arachchi; D Doheny; R J Desnick
Journal:  BMC Res Notes       Date:  2018-08-02

6.  Molecular Analysis of 55 Spanish Patients with Acute Intermittent Porphyria.

Authors:  María-José Morán-Jiménez; María-José Borrero-Corte; Fátima Jara-Rubio; Inmaculada García-Pastor; Silvia Díaz-Díaz; Francisco-Javier Castelbón-Fernandez; Rafael Enríquez-de-Salamanca; Manuel Méndez
Journal:  Genes (Basel)       Date:  2020-08-12       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.